Javascript must be enabled to continue!
Global Oncology Research and Training Collaborations Led by the National Cancer Institute (NCI)–Designated Cancer Centers: Results From the 2018 NCI/ASCO Global Oncology Survey of NCI-Designated Cancer Centers
View through CrossRef
PURPOSE The National Cancer Institute (NCI)–Designated Cancer Centers (NDCCs) are active in global oncology research and training, leading collaborations that contribute to the evidence to support global cancer control. To better understand global oncology activities led by NDCCs, the National Cancer Institute Center for Global Health (NCI-CGH) collaborated with ASCO to conduct the 2018 NCI/ASCO Global Oncology Survey of NDCCs. METHODS The 70 NDCCs received a two-part survey that focused on global oncology programs at NDCCs and non–National Institutes of Health (NIH)–funded global oncology projects with an international collaborator led by the NDCCs. Sixty-five NDCCs responded to the survey, and 57 reported non–NIH-funded global oncology projects. Data were cleaned, coded, and analyzed by NCI-CGH staff. RESULTS Thirty NDCCs (43%) report having a global oncology program, and 538 non–NIH-funded global oncology projects were reported. Of the NDCCs with global oncology programs, 17 report that trainees complete rotations outside the United States, and the same number enroll trainees from low- and middle-income countries (LMICs). In addition, 147 (28%) of the non–NIH-funded projects focused on capacity building or training, the second highest category after research. Of the 30 top project collaborator countries, 17 were LMICs. Compared with the NCI-funded international grant portfolio, non–NIH-funded global oncology projects were more likely to focus on prevention (12% NCI-funded v 20% non–NIH-funded); early detection, diagnosis, and prognosis (23% v 30%); and cancer control, survivorship, and outcomes research (13% v 22%). CONCLUSION This survey shows that there is a substantial amount of global oncology research and training supported by NDCCs, and much of this is happening in LMICs. Results of the 2018 Global Oncology Survey can be used to foster opportunities for NDCCs to work collaboratively on activities and to share their findings with relevant stakeholders in their LMIC collaborator countries.
American Society of Clinical Oncology (ASCO)
Title: Global Oncology Research and Training Collaborations Led by the National Cancer Institute (NCI)–Designated Cancer Centers: Results From the 2018 NCI/ASCO Global Oncology Survey of NCI-Designated Cancer Centers
Description:
PURPOSE The National Cancer Institute (NCI)–Designated Cancer Centers (NDCCs) are active in global oncology research and training, leading collaborations that contribute to the evidence to support global cancer control.
To better understand global oncology activities led by NDCCs, the National Cancer Institute Center for Global Health (NCI-CGH) collaborated with ASCO to conduct the 2018 NCI/ASCO Global Oncology Survey of NDCCs.
METHODS The 70 NDCCs received a two-part survey that focused on global oncology programs at NDCCs and non–National Institutes of Health (NIH)–funded global oncology projects with an international collaborator led by the NDCCs.
Sixty-five NDCCs responded to the survey, and 57 reported non–NIH-funded global oncology projects.
Data were cleaned, coded, and analyzed by NCI-CGH staff.
RESULTS Thirty NDCCs (43%) report having a global oncology program, and 538 non–NIH-funded global oncology projects were reported.
Of the NDCCs with global oncology programs, 17 report that trainees complete rotations outside the United States, and the same number enroll trainees from low- and middle-income countries (LMICs).
In addition, 147 (28%) of the non–NIH-funded projects focused on capacity building or training, the second highest category after research.
Of the 30 top project collaborator countries, 17 were LMICs.
Compared with the NCI-funded international grant portfolio, non–NIH-funded global oncology projects were more likely to focus on prevention (12% NCI-funded v 20% non–NIH-funded); early detection, diagnosis, and prognosis (23% v 30%); and cancer control, survivorship, and outcomes research (13% v 22%).
CONCLUSION This survey shows that there is a substantial amount of global oncology research and training supported by NDCCs, and much of this is happening in LMICs.
Results of the 2018 Global Oncology Survey can be used to foster opportunities for NDCCs to work collaboratively on activities and to share their findings with relevant stakeholders in their LMIC collaborator countries.
Related Results
ASCO Clinical Practice Guideline Endorsements and Adaptations
ASCO Clinical Practice Guideline Endorsements and Adaptations
ASCO engages in the endorsement and adaptation of clinical practice guidelines to recognize the high-quality work of other guideline-developing organizations, to avoid duplication ...
619. Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Epetraborole Dose Selection for the Treatment of Patients with Mycobacterium avium Complex (MAC) Lung Disease
619. Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Epetraborole Dose Selection for the Treatment of Patients with Mycobacterium avium Complex (MAC) Lung Disease
Abstract
Background
Epetraborole (EBO) is an orally available, bacterial leucyl transfer RNA synthetase inhibitor that concentra...
LB2306. Population Pharmacokinetic (PPK), Pharmacokinetic/Pharmacodynamic attainment (PTA), and Clinical Pharmacokinetic/Pharmacodynamic (PK/PD) Analyses for Sulbactam-Durlobactam (SUL-DUR) to Support Dose Selection for the Treatment of Acinetobacter baum
LB2306. Population Pharmacokinetic (PPK), Pharmacokinetic/Pharmacodynamic attainment (PTA), and Clinical Pharmacokinetic/Pharmacodynamic (PK/PD) Analyses for Sulbactam-Durlobactam (SUL-DUR) to Support Dose Selection for the Treatment of Acinetobacter baum
Abstract
Background
SUL-DUR is a β-lactam/β-lactamase inhibitor combination in development for the treatment of ABC infections, ...
593. Population Pharmacokinetic Model Development for Epetraborole and Mycobacterium avium Complex (MAC) Lung Disease Patients Using Data from Phase 1 and 2 Studies
593. Population Pharmacokinetic Model Development for Epetraborole and Mycobacterium avium Complex (MAC) Lung Disease Patients Using Data from Phase 1 and 2 Studies
Abstract
Background
Epetraborole (EBO), an orally available bacterial leucyl transfer RNA synthetase inhibitor with potent activ...
Evaluation of NCI Designated Cancer Centers medical student education and training initiatives.
Evaluation of NCI Designated Cancer Centers medical student education and training initiatives.
9032
Background:
The rising incidence of common cancers, an aging oncology workforce, and workforce shortages underscore the importanc...
Romanya Cephesinde Osmanlı 6’ncı Kolordusu’nun Harp Sahası
Romanya Cephesinde Osmanlı 6’ncı Kolordusu’nun Harp Sahası
Osmanlı Devleti, Birinci Dünya Savaşı’nda sınırları dışında Romanya, Galiçya ve Makedonya cephelerinde İttifak devletlerine (Almanya, Avusturya-Macaristan ve Bulgaristan) insan güc...
Analysis of hematology and oncology fellowship website content and diversity representation.
Analysis of hematology and oncology fellowship website content and diversity representation.
11004 Background: Fellowship in hematology and oncology (HO) is widely sought after but lags behind all other internal medicine subspecialties in attracting applicants underrepres...
Abstract LB-89: A combined epigenetic and genetic biomarker panel for detection of lung cancer.
Abstract LB-89: A combined epigenetic and genetic biomarker panel for detection of lung cancer.
Abstract
Introduction: Lung cancer is the leading cause of cancer-related deaths in human. However, there is no valid screening procedure or test available at the pr...

